M&A Deal Summary |
|
|---|---|
| Date | 2009-05-06 |
| Target | GlaxoSmithKline - Wellbutrin XL |
| Sector | Life Science |
| Buyer(s) | Biovail |
| Sellers(s) | GlaxoSmithKline |
| Deal Type | Divestiture |
| Deal Value | 510M USD |
SEARCH BY
Try For Free 7-Day Free Trial
Biovail Corp. is a specialty pharmaceutical company engaged in the formulation, clinical testing, registration, manufacture, and commercialization of pharmaceutical products. The Company is focused on the development and commercialization of medicines that address unmet medical needs in niche specialty central nervous system (CNS) markets.
| DEAL STATS | # |
|---|---|
| Overall | 2 of 3 |
| Sector (Life Science) | 2 of 3 |
| Type (Divestiture) | 1 of 2 |
| Country (United States) | 2 of 3 |
| Year (2009) | 1 of 1 |
| Size (of disclosed) | 1 of 2 |
| DATE | TARGET | DEAL TYPE | VALUE |
|---|---|---|---|
| 2008-09-17 |
Prestwick Pharmaceuticals
Washington, District of Columbia, United States Prestwick Pharmaceuticals, Inc. is a privately held, U.S.-based pharmaceutical company that holds the Canadian and U.S. licensing rights to Xenazine(R) (tetrabenazine tablets). |
Buy | - |
| DATE | TARGET | DEAL TYPE | VALUE |
|---|---|---|---|
| 2010-03-26 |
Cortex Pharmaceuticals - AMPAKINE Compounds
Irvine, California, United States Cortex Pharmaceuticals - AMPAKINE Compounds include the Phase 2 compound CX717, the preclinical compounds CX1763 and CX1942, and the injectable dosage form of CX1739. CX717 modulates AMPA-type glutamate receptors and is in development to prevent respiratory depression in the surgical setting. The incidence of respiratory depression related to opioid administration has been estimated to be up to 17% when oxygen desaturation is used as the indicator. |
Buy | $10M |
| Category | Company |
|---|---|
| Founded | 1715 |
| Sector | Life Science |
| Employees | 94,066 |
| Revenue | 34.1B GBP (2020) |
GlaxoSmithKline is a multinational pharmaceutical, biologics, vaccines and consumer healthcare company. GlaxoSmithKline was founded in 1715 and is based in Brentford, the United Kingdom.
| DEAL STATS | # |
|---|---|
| Overall | 3 of 24 |
| Sector (Life Science) | 2 of 17 |
| Type (Divestiture) | 3 of 23 |
| Country (United States) | 3 of 4 |
| Year (2009) | 1 of 1 |
| Size (of disclosed) | 5 of 9 |
| DATE | TARGET | DEAL TYPE | VALUE |
|---|---|---|---|
| 2009-04-20 |
Stiefel Laboratories
Research Triangle Park, North Carolina, United States Stiefel Laboratories, Inc. is enthusiastically committed to advancing dermatology and skin science around the world. The company’s deeply-rooted dedication and drive for innovation along with its sole focus on dermatology has led Stiefel to become the largest independent dermatology company in the world. In addition to more than 30 wholly-owned subsidiaries, six manufacturing plants and a global research and development network, Stiefel’s most valuable asset is its global network of nearly 3,500 driven associates. |
Buy | $2.9B |
| DATE | TARGET | DEAL TYPE | VALUE |
|---|---|---|---|
| 2009-05-12 |
Aspen Pharmacare
Durban, South Africa Aspen Pharmacare is a global player in specialty, branded and generic pharmaceuticals, Aspen has an extensive basket of products that provide treatment for a broad spectrum of acute and chronic conditions experienced through all stages of life. The Group continues to increase the number of lives benefitting from its products, reaching more than 150 countries. In line with the Group’s commercial, production and territorial strategies, Aspen has identified thrombosis, anaesthetics, high potency & cytotoxics and infant nutritionals as four therapeutic categories which will get the highest focus based on materiality and future potential. Aspen Pharmacare was founded in 1850 and is based in Durban, South Africa. |
Buy | - |
